"Dr Boshoff is the ideal leader to propel Pfizer's R&D engine forward and transform it into a world-leading organisation with ...

Rather than bribing and wheedling physicians to pretty-please-prescribe-our-drug, websites allow companies to deal drugs ...

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the year. Demand for the drugmaker’s Paxlovid treatment spurred by the ...

It ultimately raked in billions of dollars in sales for the first approved COVID-19 vaccine. Pfizer also made a fortune with ...

Pfizer said on Wednesday it has named company veteran and oncology head Chris Boshoff as its chief of research and ...

Pfizer's stock appears undervalued with a high dividend yield of 6.8%, making it a potential long-term investment despite low growth expectations. The company reported strong Q3 results with 31.2% YoY ...

As for his soon-to-be former role, Boshoff will be succeeded by Dr. Roger Dansey, who will serve as the interim chief ...

Chris Boshoff will take on the role of chief scientific officer starting Jan 1 & oversee all functions of research & development across all therapeutic area ...

Paxlovid sales surge to $2.7 billion, beating expectations Pfizer raises annual revenue forecast for COVID products to $10.5 billion Pfizer management faces pressure from activist hedge fund ...

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the year.